Abstract: This disclosure relates to a nucleic acid comprising a double stranded RNA molecule comprising sense and antisense strands and further comprising a single stranded DNA molecule covalently linked to the 3? end of either the sense or antisense RNA part of the molecule.

Abstract: This disclosure relates to a nucleic acid comprising a double stranded RNA molecule comprising sense and antisense strands and further comprising a single stranded DNA molecule covalently linked to the 3? end of either the sense or antisense RNA part of the molecule wherein the double stranded inhibitory RNA targets proprotein convertase subtilisin kexin type 9 (PCSK9); pharmaceutical compositions comprising said nucleic acid molecule and methods for the treatment of diseases associated with increased levels of PCSK9, for example hypercholesterolemia and cardiovascular disease.

Abstract: This disclosure relates to a nucleic acid comprising a double stranded RNA molecule comprising sense and antisense strands and further comprising a single stranded DNA molecule covalently linked to the 3? end of either the sense or antisense RNA part of the molecule wherein the double stranded inhibitory RNA targets apolipoprotein B in the treatment hypercholesterolemia.